Search This Blog

Wednesday, October 28, 2026

SELLAS triggers final overall survival analysis in pivotal Phase 3 REGAL galinpepimut-S AML trial

 

 topline primary endpoint results due this quarter

  • REGAL study reached the pre-specified 80th event required to initiate the final overall-survival analysis.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)